JG
Julie Giblin
Director Quality Assurance at Orchard Therapeutics
View Julie's Contact Info for Free. Sign Up and Get 50 Free Contacts Per Month.Get Started for Free
Work Experience
Director Quality Assurance
Nov 2018 - Present · 6 years and 1 months
Director International Qa
Aug 2016 - Nov 2018 · 2 years and 3 months
Director Quality
Sep 2015 - Mar 2016 · 6 months
Company Details
201-500 Employees
At Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment. In 2018, the company acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard is advancing a pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com,
Year Founded
2015
Social Media
LinkedinTwitter
Industry
Biotechnology
HQ Location
245 Hammersmith Road 3rd Floor London, United Kingdom W6 8PW, GB
Keywords
Stem cell technologyGene therapyOrphan diseasesand Paediatric diseasesRare diseasesGenetic diseases
Discover More About Cleveland Clinic

Find verified contacts of Julie Giblin in seconds from 700M people profiles. Start now!

No Credit Card Needed. By signing up, you understand and agree to Futern's Terms and Policy.